Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Simcere Will Co-Develop Cancer Drugs With BMS; A New R&D Model Between China And U.S.?

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - While reporting strong growth in the third quarter, New York-listed Chinese pharma Simcere focused attention on its recent deal with Bristol-Myers Squibb to co-develop BMS-817378, a small molecule MET/VEGFR-2 inhibitor now in preclinical development

You may also be interested in...



Will Going Private Jeopardize Simcere’s Status As A Partner Of Choice For Big Pharma?

Among U.S-listed Chinese pharmaceutical companies, Simcere has been ahead of the curve in snatching up deals with multinationals. As the Nanjing-based company gets closer to going private, could that status be a concern for potential suitors?

BMS Tests Virtual R&D Network In China For Orencia Deal With Simcere

BMS has been trying since 2012 to figure out a way to bring its first biologic product to China. Now, the company will partner with Simcere to hasten development of its $1.2 billion rheumatoid arthritis blockbuster Orencia.

BMS Tests Virtual R&D Network In China For Orencia Deal With Simcere

BMS has been trying since 2012 to figure out a way to bring its first biologic product to China. Now, the company will partner with Simcere to hasten development of its $1.2 billion rheumatoid arthritis blockbuster Orencia.

Related Content

UsernamePublicRestriction

Register

LL1123310

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel